RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/20173784http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/20173784http://www.w3.org/2000/01/rdf-schema#comment"The effect of natural killer (NK) cell alloreactivity on the outcome of unrelated hematopoietic SCT (HSCT) remains a topic of debate. NK cell alloreactivity after allogeneic HSCT is regulated by killer-cell Ig-like receptors (KIRs). To investigate the influence of KIRs on outcome after unrelated HSCT, we retrospectively analyzed the HLA and KIR genotypes of 116 donor-recipient pairs. We found that missing KIR ligands in recipients were significantly associated with a decreased leukemic relapse risk (P=0.019, HR=0.329), mainly in myeloid disease (P=0.003, HR=0.193). This beneficial effect was seen in AML/myelodysplastic syndrome and also in chronic myeloid leukemia. In myeloid disease, missing KIR ligands also improved 5-year OS (P=0.034, HR=0.430) and disease-free survival (DFS) (P=0.024, HR=0.445). Meanwhile, the presence of donor-activating KIR2DS3 gene was associated with increased relapse risk (P=0.003, HR=5.046), decreased OS (P=0.004, HR=3.181) and DFS (P=0.003, HR=2.919) in myeloid disease. No effect was seen in patients with lymphoid disease. Our study indicated that, in unrelated HSCT for myeloid leukemia, missing KIR ligands in recipients offered a lower relapse risk and a long-term survival advantage. The presence of KIR2DS3 in the donor was an important risk factor for myeloid leukemia."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.org/dc/terms/identifier"doi:10.1038/bmt.2010.3"xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Cai Z."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Huang H."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Li L."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Luo Y."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Zhang J."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Lin M.F."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"He J.S."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Tan Y.M."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Zhao Y.M."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Zheng W.Y."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Lai X.Y."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Wu G.Q."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Jin A.Y."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Hu X.R."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Shi J.M."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Ye X.J."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/author"Xie W.Z."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/date"2010"xsd:gYear
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/name"Bone Marrow Transplant"xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/pages"1514-1521"xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/title"The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population."xsd:string
http://purl.uniprot.org/citations/20173784http://purl.uniprot.org/core/volume"45"xsd:string